Martin Felsenthal is a venture capital and growth-stage investor who has focused exclusively on investing in and working with innovative health care services and health care software companies since 1992. He has provided capital to a number of companies that helped create new industries in health care and to companies that became market leaders, including TelaDoc; change: healthcare (acquired by Emdeon); Aperio (acquired by Leica Biosystems); Titan Health (acquired by United Surgical Partners); US Renal Care (acquired by Leonard Green); Payerpath (acquired by Misys/Allscripts); Vantage Oncology (acquired by McKesson); NovoLogix (acquired by CVS Health); VeriCare (acquired by MedOptions); OnShift; and ClearData Networks.

As an investor, Felsenthal has leveraged his relationships in the health care sector to help initiate, sustain, or expand significant customer relationships for more than one-third of his portfolio companies; has helped recruit more than 50 executives to the companies with whom he worked; and has been fortunate to have outperformed the venture benchmark returns in each of his fund vintage years. During his career, he has invested on behalf of financial limited partners as well as in partnership with some of the nation’s largest and most influential health care payers, health systems, pharmacy chains, and health care foundations.

Felsenthal has an undergraduate degree from Princeton University and a master’s degree in business administration from the Stanford University Graduate School of Business.